Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
Mené sur 1 034 patients atteints d'un cancer avancé du poumon non à petites cellules exprimant PD-L1 dans plus de 1% des cellules tumorales, cet essai randomisé international évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du pembrolizumab
Are we ready to embrace the routine use of immune checkpoint inhibitors in patients with advanced stage non-small-cell lung cancer? In The Lancet, Roy Herbst and colleagues report the results of KEYNOTE-010, a randomised phase 2/3 study in 202 academic medical centres in 24 countries that compared two doses of pembrolizumab (2 mg/kg and 10 mg/kg) with docetaxel (75 mg/m2) every 3 weeks in 1034 patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. This biomarker-enriched study had two primary endpoints of overall survival and progression-free survival both in the total population and in the subgroup of patients with tumour proportion score of 50% or more, which is defined as the percentage of tumour cells expressing PD-L1 assessed by immunohistochemistry using antibody 22C3.
The Lancet , commentaire, 2014